Comment from Young Lung Cancer Initiative

Summary: The Young Lung Cancer Initiative, a patient advocacy organization, supports the Citizen Petition requesting that the FDA mandate a Limitation of Use on immunotherapy labeling for NSCLC. They argue that patients with ROS1 and RET rearrangements (who are often younger) should be excluded from first-line immunotherapy to prevent ineffective treatment and ensure they receive more effective targeted therapies.